Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: Subgroup analyses from two randomized trials

Ophthalmology

Volumn 122, Issue 1, 2015, Pages 117-122

  Haller, Julia A ^a   Stalmans, Peter ^b   Benz, Matthew S ^c   Gandorfer, Arnd ^d,e   Pakola, Stephen J ^f   Girach, Aniz ^g   Kampik, Anselm ^h   Jaffe, Glenn J ⁱ   Toth, Cynthia A ⁱ  

^a WILLS EYE HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c RETINA CONSULTANTS OF HOUSTON   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Diagnostik München   (Germany)

^f Amakem Therapeutics   (Belgium)

^g NightstaRx Ltd   (United Kingdom)

^h DUKE UNIVERSITY EYE CENTER   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

OCRIPLASMIN; PLACEBO; FIBRINOLYTIC AGENT; PEPTIDE FRAGMENT; PLASMIN;

ADULT; AGED; ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA HOLE; RETINA MACULOPATHY; SINGLE DRUG DOSE; VISUAL ACUITY; VITRECTOMY; VITREOMACULAR ADHESION; VITREOMACULAR TRACTION; VITREOUS DISEASE; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; EYE DISEASES; FOCAL ADHESION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINAL DISEASES; TREATMENT OUTCOME; VERY ELDERLY; VITREOUS BODY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; EYE DISEASES; FEMALE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; FOCAL ADHESIONS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; YOUNG ADULT;

EID: 84920722581     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.045     Document Type: Article

References (18)

1. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-8.
2. Uchino E, Uemura A, Ohba N. Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 2001;119:1475-9.
3. Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol 2010;149:371-82.
4. ICD-9 Diagnosis Codes. 2013 ICD-9 Diagnosis Codes - index. Other disorders of eye 379. Available at: http://www.icd9data.com/2013/Volume1/320-389/360-379/379/default.htm. Accessed July 29, 2014.
5. Girach A, Pakola S. Vitreomacular interface diseases: pathophysiology, diagnosis and future treatment options. Expert Rev Ophthalmol 2012;7:311-23.
6. Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc 2005;103:473-94.
7. Sebag J. Pharmacologic vitreolysis-premise and promise of the first decade. Retina 2009;29:871-4.
8. Rheaume MA, Vavvas D. Pharmacologic vitreolysis. Semin Ophthalmol 2010;25:295-302.
9. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 2011;5:1151-65.
10. Jetrea (ocriplasmin) Intravitreal Injection, 2.5 mg/mL [package insert]. Iselin, NJ: ThromboGenics, Inc.; May 2014.
11. European Medicines Agency. Jetrea. Annex I: Summary of product characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002381/human-med-001629.jsp&mid=WC0b01ac058001d124. Accessed July 29, 2014.
12. Chen W, Mo W, Sun K, et al. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res 2009;34:1057-64.
13. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004;45:641-7.
14. de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci 2009;50:814-9.
15. de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology 2009;116:1349-55.
16. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 2010;117:791-7.
17. Stalmans P, Delaey C, de Smet MD, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina 2010;30:1122-7.
18. Stalmans P, Benz MS, Gandorfer A, et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012;367:606-15.